<DOC>
	<DOCNO>NCT01892176</DOCNO>
	<brief_summary>The investigator hypothesise measure biomarkers oxidative damage could better inform investigator potential merit ( pitfall ) CoQ10 supplementation PD subject .</brief_summary>
	<brief_title>Effects High-dose Coenzyme Q10 Biomarkers Oxidative Damage Clinical Outcome Parkinson Disease</brief_title>
	<detailed_description>Subjects idiopathic PD recruit 10-week dose escalation study . Each dosage ( 400mg/day , 800mg/day , 1200/day 2400mg/day ) consume daily two week . Information safety fast blood/urine sample collect . Primary endpoint plasma F2-isoprostanes ( adjust arachidonate ) secondary endpoint change total Unified Parkinson Disease Rating Scale ( UPDRS ) treatment . Serum phospholipase A2 activity , plasma trans-retinol , plasma total tocopherol ( sum α- , δ- γ-tocopherol ) serum uric acid measure .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Coenzyme Q10</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<criteria>idiopathic Parkinson disease age &gt; 21 year able provide write informed consent diabetes mellitus , stroke , cardiac renal disease cigarette smoke major psychiatric disorder drug and/or alcohol abuse/dependence regular use antioxidant , dietary supplement , traditional Chinese remedy , nonsteroidal antiinflammatory drug immunosuppressive drug</criteria>
	<gender>All</gender>
	<minimum_age>21 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>coenzyme Q10 , Parkinson disease , oxidative damage</keyword>
</DOC>